Orphazyme delays its first expected approval until 2021
Orphazyme now expects its drug arimoclomol to be approced in 2021, having previously announced that this was expected in the second half of 2020. The reason for this delay can be characterized as better safe than sorry.
Listed biotech company Orphazyme has quietly delayed its timeline for one of the most important events in the company's history.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
